1
|
Infliximab maintenance therapy for fistulizing Crohn's disease.
|
N Engl J Med
|
2004
|
6.77
|
2
|
A prospective study of long-term intake of dietary fiber and risk of Crohn's disease and ulcerative colitis.
|
Gastroenterology
|
2013
|
4.06
|
3
|
Higher predicted vitamin D status is associated with reduced risk of Crohn's disease.
|
Gastroenterology
|
2011
|
3.84
|
4
|
Risks and benefits of infliximab for the treatment of Crohn's disease.
|
Clin Gastroenterol Hepatol
|
2006
|
2.88
|
5
|
Treatment of active Crohn's disease with recombinant human granulocyte-macrophage colony-stimulating factor.
|
Lancet
|
2002
|
2.74
|
6
|
LRRK2 is involved in the IFN-gamma response and host response to pathogens.
|
J Immunol
|
2010
|
1.85
|
7
|
Non-invasive mapping of the gastrointestinal microbiota identifies children with inflammatory bowel disease.
|
PLoS One
|
2012
|
1.66
|
8
|
Dysregulation of Reg gene expression occurs early in gastrointestinal tumorigenesis and regulates anti-apoptotic genes.
|
Cancer Biol Ther
|
2006
|
1.63
|
9
|
Probiotics to minimize the disruption of faecal microbiota in healthy subjects undergoing antibiotic therapy.
|
J Med Microbiol
|
2009
|
1.58
|
10
|
Transition of adolescents with inflammatory bowel disease from pediatric to adult care: a survey of adult gastroenterologists.
|
J Pediatr Gastroenterol Nutr
|
2009
|
1.22
|
11
|
Physical activity and risk of inflammatory bowel disease: prospective study from the Nurses' Health Study cohorts.
|
BMJ
|
2013
|
1.18
|
12
|
Association of glycogen storage disease 1b and Crohn disease: results of a North American survey.
|
Eur J Pediatr
|
2002
|
1.11
|
13
|
Probiotics for recurrent Clostridium difficile disease.
|
J Med Microbiol
|
2005
|
1.06
|
14
|
Impact of coexistent celiac disease on phenotype and natural history of inflammatory bowel diseases.
|
Am J Gastroenterol
|
2013
|
1.05
|
15
|
Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients: A Multicenter Cohort.
|
Inflamm Bowel Dis
|
2015
|
0.99
|
16
|
Serological response to the 2009 H1N1 influenza vaccination in patients with inflammatory bowel disease.
|
Gut
|
2011
|
0.97
|
17
|
Chemical and cytokine features of innate immunity characterize serum and tissue profiles in inflammatory bowel disease.
|
Proc Natl Acad Sci U S A
|
2013
|
0.97
|
18
|
Analysis of treatment effects on the microbial ecology of the human intestine.
|
FEMS Microbiol Ecol
|
2006
|
0.96
|
19
|
Inflammatory bowel disease and environmental influences.
|
Gastroenterol Clin North Am
|
2002
|
0.95
|
20
|
Can mucosal healing be a cost-effective endpoint for biologic therapy in Crohn's disease? A decision analysis.
|
Inflamm Bowel Dis
|
2013
|
0.93
|
21
|
Distinct microbiome in pouchitis compared to healthy pouches in ulcerative colitis and familial adenomatous polyposis.
|
Inflamm Bowel Dis
|
2010
|
0.92
|
22
|
Efficacy and safety of natalizumab in Crohn's disease patients treated at 6 Boston academic hospitals.
|
Inflamm Bowel Dis
|
2013
|
0.92
|
23
|
Marijuana use patterns among patients with inflammatory bowel disease.
|
Inflamm Bowel Dis
|
2013
|
0.92
|
24
|
Characterization of patients with infliximab-induced lupus erythematosus and outcomes after retreatment with a second anti-TNF agent.
|
Inflamm Bowel Dis
|
2011
|
0.89
|
25
|
Growth factors as treatment options for intestinal inflammation.
|
Ann N Y Acad Sci
|
2006
|
0.86
|
26
|
Certolizumab pegol compared to natalizumab in patients with moderate to severe Crohn's disease: results of a decision analysis.
|
Dig Dis Sci
|
2011
|
0.86
|
27
|
Barriers to enrollment in inflammatory bowel disease randomized controlled trials: an investigation of patient perspectives.
|
Inflamm Bowel Dis
|
2012
|
0.85
|
28
|
Validation of interactive voice response system administration of the Short Inflammatory Bowel Disease Questionnaire.
|
Inflamm Bowel Dis
|
2009
|
0.85
|
29
|
Risk Factors for Rehospitalization Within 90 Days in Patients with Inflammatory Bowel Disease.
|
Inflamm Bowel Dis
|
2015
|
0.82
|
30
|
Immediate versus tailored prophylaxis to prevent symptomatic recurrences after surgery for ileocecal Crohn's disease?
|
Surgery
|
2011
|
0.81
|
31
|
Strategies for the prevention of postoperative recurrence in Crohn's disease: results of a decision analysis.
|
Am J Gastroenterol
|
2011
|
0.81
|
32
|
Selective use of selective nonsteroidal anti-inflammatory drugs in inflammatory bowel disease.
|
Clin Gastroenterol Hepatol
|
2006
|
0.80
|
33
|
Modifiable Risk Factors for Hospital Readmission Among Patients with Inflammatory Bowel Disease in a Nationwide Database.
|
Inflamm Bowel Dis
|
2017
|
0.77
|
34
|
Factors associated with durable response to infliximab in Crohn's disease 5 years and beyond: a multicenter international cohort.
|
Inflamm Bowel Dis
|
2015
|
0.76
|
35
|
Crohn's Cartography: Mapping Disease Patterns and Trajectories Using the Lémann Index-Are We Finding Our Way?
|
J Clin Gastroenterol
|
2016
|
0.75
|
36
|
Impaired innate immune function associated with fecal supernatant from Crohn's disease patients: insights into potential pathogenic role of the microbiome.
|
Inflamm Bowel Dis
|
2014
|
0.75
|
37
|
Hospitalizations for Acute Myocardial Infarction Are Decreased Among Patients with Inflammatory Bowel Disease Using a Nationwide Inpatient Database.
|
Inflamm Bowel Dis
|
2016
|
0.75
|